• 1
    Bernay F, Bland JM, Häggström J, et al. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. J Vet Intern Med 2010;24:331341.
  • 2
    Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709717.
  • 3
    Hu Y, Carpenter JP, Cheung AT. Life-threatening hyperkalemia: A complication of spironolactone for heart failure in a patient with renal insufficiency. Anesth Analg 2002;95:3941.
  • 4
    Obialo CI, Ofili EO, Mirza T. Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease. Am J Cardiol 2002;90:663665.
  • 5
    Anton C, Cox AR, Watson RDS, Ferner RE. The safety of spironolactone treatment in patients with heart failure. J Clin Pharm Ther 2003;28:285287.
  • 6
    Svensson M, Gustafsson F, Galatius S, et al. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: Retrospective study. Brit Med J 2003;327:11411142.
  • 7
    Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004;351:543551.
  • 8
    Svensson M, Gustafsson F, Galatius S, et al. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 2004;10:297303.
  • 9
    Tamirisa KP, Aaronson KD, Koelling TM. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 2004;148:971978.
  • 10
    Desai AS, Swedberg K, McMurray JJ, et al. Incidence and predictors of hyperkalemia in patients with heart failure: An analysis of the CHARM Program. J Am Coll Cardiol 2007;50:19591966.
  • 11
    Lopes RJ, Lourenço AP, Mascarenhas J, et al. Safety of spironolactone use in ambulatory heart failure patients. Clin Cardiol 2008;31:509513.
  • 12
    Waldum B, Westheim AS, Sandvik L, et al. Renal function in outpatients with chronic heart failure. J Card Fail 2010;16:374380.
  • 13
    Shah KB, Rao K, Sawyer R, Gottlieb SS. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol 2005;46:845849.
  • 14
    Tang WH, Parameswaran AC, Maroo AP, Francis GS. Aldosterone receptor antagonists in the medical management of chronic heart failure. Mayo Clin Proc 2005;80:16231630.
  • 15
    Hulter HN, Bonner EL, Glynn RD, Sebastian A. Renal and systemic acid-base effects of chronic spironolactone administration. Am J Physiol 1981;240:F381F387.
  • 16
    Jeunesse E, Woehrle F, Schneider M, Lefebvre HP. Effect of spironolactone on diuresis and urine sodium and potassium excretion in healthy dogs. J Vet Cardiol 2007;9:6368.
  • 17
    Thomason JD, Rockwell JE, Fallaw TK, Calvert CA. Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg 2 + , and Na+ concentrations in small dogs with degenerative mitral valve disease. J Vet Cardiol 2007;9:103108.
  • 18
    Hori Y, Takusagawa F, Ikadai H, et al. Effects of oral administration of furosemide and torsemide in healthy dogs. Am J Vet Res 2007;68:10581063.
  • 19
    Sayer MB, Atkins CE, Fujii Y, et al. Acute effect of pimobendan and furosemide on the circulating renin-angiotensin-aldosterone system in healthy dogs. J Vet Intern Med 2009;23:10031006.
  • 20
    Schuller S, Van Israël N, Vanbelle S, et al. Lack of efficacy of low-dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs. J Vet Pharmacol Ther 2011;34:322331.
  • 21
    Buchanan JW, Bücheler J. Vertebral scale system to measure canine heart size in radiographs. J Am Vet Med Assoc 1995;206:194199.
  • 22
    Fox PR, Sisson D, Moise NS. Textbook of Canine and Feline Cardiology: Principles and Clinical Practice, 2nd ed. Philadelphia, PA: WB Saunders; 1999. Appendix A.
  • 23
    Guyonnet J, Elliott J, Kaltsatos V. A preclinical pharmacokinetic and pharmacodynamic approach to determine the dose of spironolactone for treatment of congestive heart failure in dog. J Vet Pharmacol Therap 2010;33:260267.
  • 24
    CVMP/VICH/595/98-FINAL. VICH Topic GL9 (GCP). Guideline on Good Clinical Practices. 4 July 2000.
  • 25
    EMA/CVMP/PhVWP/288284/2007. Guidance Notes on the Use of VeDDRA Terminology for Reporting Suspected Adverse Reactions in Animals and Humans. 14 June 2012.
  • 26
    Nicolle AP, Chetboul V, Allerheiligen T, et al. Azotemia and glomerular filtration rate in dogs with chronic valvular disease. J Vet Intern Med 2007;21:943949.
  • 27
    Clinical and Laboratory Standards Institute (CLSI). Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guidelines, CLSI document C28-A3, Vol. 28, No. 3, 3rd ed.Wayne, PA: Clinical and Laboratory Standard Institute; 2008.
  • 28
    Atkins CE, Brown WA, Coats JR, et al. Effects of long-term administration of enalapril on clinical indicators of renal function in dogs with compensated mitral regurgitation. J Am Vet Med Assoc 2002;221:654658.
  • 29
    Pouchelon JL, King J, Martignoni L, et al. Long-term tolerability of benazepril in dogs with congestive heart failure. J Vet Cardiol 2004;6:713.
  • 30
    Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006;113:671678.
  • 31
    Ritz E, McClellan WM. Overview: Increased cardiovascular risk in patients with minor renal dysfunction: An emerging issue with far-reaching consequences. J Am Soc Nephrol 2004;15:513516.
  • 32
    Bertocchio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: An emerging paradigm in chronic kidney disease. Kidney Int 2011;79:10511060.
  • 33
    Gaillard RC, Riondel AM, Chabert P, Vallotton MB. Effect of spironolactone on aldosterone regulation in man. Clin Sci (Lond) 1980;58:227233.
  • 34
    Vallotton MB, Riondel AM, Gaillard R, Guelpa-Decorzant C. Effect of spironolactone administration on plasma and urinary aldosterone in man and the rat. Prog Biochem Pharmacol 1980;17:5865.